Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.
about
Current and future directions for treating hepatitis B virus infectionAlpha-interferon treatment in hepatitis BLongitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection.Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis.Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B.Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients.Serum hepatitis B surface antigen levels and their utility as a predictor of sustained virological response after antiviral treatment.Genetic variation in the vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon: A multicenter studyVirus and Host Testing to Manage Chronic Hepatitis B.Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy.HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patientsHBsAg Quantification in Clinical Practice.Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review.Hepatitis B virus serology to predict antiviral response in chronic hepatitis B.Clinical implications of HBsAg quantification in patients with chronic hepatitis B.The role of HBsAg quantification for monitoring natural history and treatment outcome.Expert recommendations on the application of interferon for chronic hepatitis B.HBsAg quantification: useful for monitoring natural history and treatment outcome.New therapeutic perspectives in HBV: when to stop NAs.Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.How to achieve immune control in chronic hepatitis B?Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.Virological and serological tools to optimize the management of patients with chronic hepatitis B.Hepatitis B: treatment choice and monitoring for response and resistance.Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives.Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B.HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon.Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α.Effect of serum hepatitis B surface antigen levels on predicting the clinical outcomes of chronic hepatitis B infection: A meta-analysis.HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy.HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.Comparison of two immunoassays for quantification of hepatitis B surface antigen in Chinese patients with concomitant hepatitis B surface antigen and hepatitis B surface antibodies.Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis.Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B.Loss of HBsAg and antiviral treatment: from basics to clinical significance.
P2860
Q26851240-CA68B907-81A5-4CD6-B537-65DABDE920FDQ33592755-95EB0E4B-0FDF-4ABB-B02E-DE89FACC9C7AQ34598267-0092983C-9699-4DB6-BDAB-D69A30D4424EQ35250340-0DA04495-43D3-45A0-8270-7E87F313A038Q35688409-A7235DA6-232A-4F78-8313-70690DC991EEQ35973806-840FB19A-5AD7-44B4-8847-B72ECD52F99DQ36153775-C7A144D1-9F50-4C54-B9CA-2BBAF01AF899Q36220194-ECE82ACC-CB75-4944-9880-945103BCE4BFQ36309024-D69498B4-F826-47C5-A17E-CA04C4199423Q36958940-BE12DA24-3DE7-4609-857C-137E1671FA36Q36972686-414178B2-D614-4CEB-B77F-49631C7B8D53Q37374481-4D7CEF3A-BD66-4FF6-AC4B-ACD9384E9FE7Q37614037-59581489-D3C4-4965-AEA8-9E69E36434CCQ37684139-7845AB69-D587-4858-8C6F-AE62E7D8BF9EQ37866717-A17004F3-C688-4E7B-B263-4236B9E11AF8Q37966704-BF57CF3F-5911-4ACF-8D72-57A87F2B8ED8Q37994049-2178BBD6-4ED1-4225-8D0E-625C5FC4DD28Q38071397-7926053A-16A5-405A-AE62-9CA062511B7DQ38131868-FB37F8F0-7330-4581-B6BD-FF6A11E7E44BQ38174257-D96C4B1D-F0AE-4598-A4E7-134C4C4C79EBQ38174265-94006598-6600-4E60-94A4-7102DDBAAEB2Q38177851-D4CF7127-CF32-4C29-82A4-44D157C5D162Q38295840-78E4CADB-5B01-4C61-9026-BCD8907B8895Q38383489-4AA7D458-4E59-461D-BFD4-9255DB19F8D2Q38601876-2BC46804-94CB-4D75-928A-9DABCA633A38Q38685589-7CC9E99C-0385-4687-AEFA-372B441A9401Q38707903-8D69B954-7EFA-4153-A07B-C2B7636ABBB8Q39298929-35407A4F-5B4E-4856-A59C-E64205319BE8Q39388862-35236977-96F9-4CBB-A381-B5306C0A2887Q40102464-91B00F65-0F4E-4744-93E9-BED1A6A6D433Q40161294-85102B5F-3A00-407D-A1BA-C7BC3DB47D21Q40335324-2426B081-9FF0-4ECC-9038-59ABB9C8EB98Q40557516-3C236680-E08C-49F4-9647-A8E7B73E9BECQ41684870-3D56A4EF-2A3E-41DB-9836-CA3011F8CC0CQ41718138-1CC24732-A9EE-4049-9E1F-2AA132059B66Q41986565-2FE19BD5-38A1-4D13-B453-76D22BADB2F6Q42183410-7044E4E0-DAB7-4DA9-A804-D0EE3983885FQ42225934-F3CA4217-64AC-447E-A869-4E97E50D0ABAQ42228903-1635E77B-DC27-4060-9FAD-3AE8226A866AQ42235230-104A275E-0FE7-47B6-A8B1-21FDCB49AF0A
P2860
Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Serum HBsAg quantification to ...... positive chronic hepatitis B.
@en
Serum HBsAg quantification to ...... positive chronic hepatitis B.
@nl
type
label
Serum HBsAg quantification to ...... positive chronic hepatitis B.
@en
Serum HBsAg quantification to ...... positive chronic hepatitis B.
@nl
prefLabel
Serum HBsAg quantification to ...... positive chronic hepatitis B.
@en
Serum HBsAg quantification to ...... positive chronic hepatitis B.
@nl
P2093
P2860
P1476
Serum HBsAg quantification to ...... n positive chronic hepatitis B
@en
P2093
P2860
P304
P356
10.1111/J.1365-2036.2010.04474.X
P407
P577
2010-09-29T00:00:00Z